ARTICLE | Management Tracks
Plus: Accent’s Copeland to retire and updates from ProQR, Kashiv and Aculeus
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
December 12, 2024 1:16 AM UTC
Xaira Therapeutics Inc. continued building out its C-suite, naming Paulo Fontoura CMO and co-founder Hetu Kamisetty CTO. Fontoura was SVP neuroscience, immunology, ophthalmology, infectious and rare diseases at Roche (SIX:ROG; OTCQB:RHHBY). Xaira launched in April with a $1 billion venture round led by Arch Venture Partners and Foresite Capital and a license to a de novo computational antibody design technology from the lab of co-founder and 2024 Nobel Laureate David Baker.
CSO Robert Copeland will retire from Accent Therapeutics Inc. on Dec. 31. Copeland, who co-founded the RNA epigenetics company in 2017, will be succeeded by VP of Biology Serena Silver…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654446/two-more-c-suite-hires-at-xaira